{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:00:07Z","timestamp":1780995607855,"version":"3.54.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A case of severe coagulopathy induced by treatment with cefazolin and rifampin is described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A 72-year-old male presented for generalized weakness accompanied by chills and fevers. Infectious workup revealed methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia and mechanical aortic valve endocarditis with perivalvular abscess. The patient was initially treated with intravenous cefazolin and gentamicin until surgical valve replacement. His postoperative course was complicated by acute kidney injury, and antimicrobial therapy was transitioned to cefazolin and rifampin. On postoperative day 10, the patient acutely developed hypotension requiring vasopressor support and respiratory failure secondary to volume overload requiring initiation of continuous renal replacement therapy. Significant oozing was observed from puncture sites and large-volume hemoptysis. Coagulation studies revealed an undetectable international normalized ratio (INR) and prothrombin time (PT) and a prolonged activated partial thromboplastin time (aPTT). In the absence of alternative causes, rifampin-induced coagulopathy was implicated as the probable cause. Prescribing information for rifampin provides a warning for concomitant therapy with cefazolin and rifampin due to a risk of prolonged PT and severe vitamin K\u2013dependent coagulation disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current guidelines recommend treatment of MSSA prosthetic valve endocarditis with combination therapy consisting of cefazolin or an antistaphylococcal penicillin and rifampin, with the addition of gentamicin for the first 2 weeks of therapy. Rifampin-induced coagulopathy and cefazolin-induced coagulopathy due to hypoprothrombinemia have been rarely reported. Concomitant therapy with rifampin and cefazolin may exacerbate coagulopathy, particularly in the setting of renal dysfunction, thus coagulation studies should be closely monitored if combination therapy is indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag010","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:44:05Z","timestamp":1767789845000},"page":"616-622","source":"Crossref","is-referenced-by-count":2,"title":["Coagulopathy induced by treatment with cefazolin and rifampin: A case report"],"prefix":"10.1093","volume":"83","author":[{"given":"Hannah F","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital of the University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P","family":"Hecht","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Trinity Health Ann Arbor Hospital , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"15","key":"2026060904150105900_zxag010-B1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"2026060904150105900_zxag010-B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijantimicag.2018.09.014","article-title":"An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC)","volume":"53","author":"Saeed","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026060904150105900_zxag010-B3","author":"Rifadin"},{"issue":"1","key":"2026060904150105900_zxag010-B4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2026060904150105900_zxag010-B5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40121-019-00259-4","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with methicillin-susceptible Staphylococcus aureus Infection: a meta-analysis with trial sequential analysis","volume":"8","author":"Allen","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"5","key":"2026060904150105900_zxag010-B6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jiph.2018.02.004","article-title":"Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Monogue","year":"2018","journal-title":"J Infect Public Health"},{"issue":"10","key":"2026060904150105900_zxag010-B7","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"2026060904150105900_zxag010-B8","doi-asserted-by":"publisher","first-page":"A1047","DOI":"10.1016\/j.chest.2022.08.828","article-title":"Cefazolin-induced coagulopathy","volume":"162","author":"Goldberg","year":"2022","journal-title":"Chest"},{"issue":"6","key":"2026060904150105900_zxag010-B9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/08998280.2022.2095859","article-title":"Cefazolin-induced hypoprothrombinemia","volume":"35","author":"Smith","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)."},{"issue":"9","key":"2026060904150105900_zxag010-B10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2146\/ajhp070243","article-title":"Cefazolin-induced hypoprothrombinemia","volume":"65","author":"Chung","year":"2008","journal-title":"Am J Health-Syst Pharm."},{"issue":"1","key":"2026060904150105900_zxag010-B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/idr13010021","article-title":"Deranged coagulation profile secondary to cefazolin use: case report","volume":"13","author":"Ngiam","year":"2021","journal-title":"Infect Dis Rep"},{"issue":"24","key":"2026060904150105900_zxag010-B12","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/ajhp\/zxab210","article-title":"Cefazolin and rifampin: a coagulopathy-inducing combination","volume":"78","author":"Castillo Almeida","year":"2021","journal-title":"Am J Health-Syst Pharm"},{"issue":"5","key":"2026060904150105900_zxag010-B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5194\/jbji-6-131-2021","article-title":"Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous","volume":"6","author":"Kouki","year":"2021","journal-title":"J Bone Jt Infect"},{"issue":"5","key":"2026060904150105900_zxag010-B14","doi-asserted-by":"publisher","first-page":"003380","DOI":"10.12890\/2022_003380","article-title":"Deranged haemostasis: rifampin-induced coagulopathy","volume":"9","author":"Tiperneni","year":"2022","journal-title":"Eur J Case Rep Intern Med"},{"issue":"5","key":"2026060904150105900_zxag010-B15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1365-2125.2011.04158.x","article-title":"Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus","volume":"73","author":"Sampaziotis W","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026060904150105900_zxag010-B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag010\/66313506\/zxag010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/12\/616\/66313506\/zxag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/12\/616\/66313506\/zxag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:15:25Z","timestamp":1780992925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/12\/616\/8417642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag010","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,1,8]]}}}